Shortly after pumping $50M into Indiana site, Catalent will hire up to 600 new employees
Moderna’s vaccine manufacturing partner Catalent has spent all of 2021 capitalizing on the massive demand for vaccine manufacturing and expanding its operations through mergers, acquisitions and site build outs. Now, it’s time to staff those facilities.
The Somerset, NJ manufacturer had two job fairs last week at the Monroe County Convention Center in hopes of staffing its site in Bloomington, IN. The company is hiring for jobs ranging from director to technicians, and especially entry-level roles in manufacturing and the warehouse. Catalent will try to hire between 500 and 600 employees.
Senior director of human resources Arturo Lopez told The Herald-Times that the company is in part upping production because of Covid-19 vaccines because of demand, and the company expects to keep up for both initial shots and boosters. Catalent has invested more than $250 million in Monroe County since 2019, and that number is expected to grow. The local site currently has 3,500 employees.
In September 2020, Catalent acquired the 23,000 square-foot site from AB BioTechnologies and outfitted it in time for operations to start at the beginning of this year. Around 40 people were hired to staff the new site, which featured a small-scale filling line, used primarily for early phase clinical trials.
Catalent expanded its deal with Moderna in April to churn out double the number of finished vials of the vaccine to 400 vials per minute at the Bloomington site. Moderna will have a dedicated filling line in Bloomington through 2023.
Entry-level pay starts at $18 per hour, and employees are set to get benefits from the start. The Herald-Times reported that the state’s unemployment rate was down to 4.1% in August, roughly 3.2% lower than what it was in August 2020.
There’s been a battle for top talent in pharmaceutical manufacturing as of late, as companies continue to quickly ramp up supply agreements and expand operations, largely due to the massive increase in demand for biologics and vaccines. In the last year, Catalent has expanded at sites in Madison, WI and Anagni, Italy.
Catalent’s earnings have increased 159% in the past year to $585 million. The company’s stock price this year is up 27%.